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Abstract
Background: The aim of our study was to evaluate the
between-assay variability of commercially available immuno-
assays for the measurement of human growth hormone
(hGH). In addition, we asked whether the comparability of
the diagnosis of childhood onset growth hormone deficiency
could be improved by adjusting hGH results by statistical
methods, such as linear regression, conversion factors, and
quantile transformation.
Methods: In archived sera from 312 children and adoles-
cents (age: 17 days–17 years) hGH values between 0.01 and
16.5 ng/mL were determined by using the following immuno-
assays: AutoDELFIA (PerkinElmer), BC-IRMA (Beckman-
Coulter), ELISA (Mediagnost), IMMULITE 2000 (Siemens),
iSYS (IDS), Liaison (DiaSorin), UniCel DxI 800 Access
(BeckmanCoulter) and ‘‘In house’’-RIA (Tu¨bingen).
Results: The assays differed in median hGH concentrations
by as much as 5.44 ng/mL (Immulite), and as little as
2.67 ng/mL (BC-IRMA). The mean difference between
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assays ranged from 0.35 to 2.71 ng/mL, whereas several
samples displayed differences up to 11.4 ng/mL. The best
correlation (rs0.992) was found between AutoDELFIA and
Liasion, the lowest (rs0.864) was between an in-house RIA
and iSYS. The between-assay CV (mean"SD) of values
within the cut-off range was 24.3%"7.4%, resulting in an
assay-dependent diagnosis of growth hormone deficiency
(GHD) in more than 27% of patients. Yet, adjustment of this
data by linear regression or a conversion factor reduced the
CV below 14%, and the ratio of assay-dependent diagnoses
below 8%. Using quantile transformation, the CV and ratio
were reduced to 11.4% and -1%, respectively.
Conclusions: hGH measurements using different assays vary
significantly. Linear regression, conversion factors, or partic-
ularly quantile transformation are useful tools to improve
comparability in the diagnostic procedure for the confirma-
tion of GHD in childhood and adolescence.
Keywords: adolescents; children; growth hormone deficien-
cy; immunoassay; short stature.
Introduction
The prevalence for growth hormone deficiency (GHD) in
children and adolescents is estimated to be between 1:4000
and 1:20,000 (1). After exclusion of other causes of short
stature, growth velocity below the 25th percentile in com-
bination with bone age retardation by more than one standard
deviation (SD) and insulin-like growth factor-I (IGF-I), and/
or IGF-binding protein (IGFBP)-3 concentrations below -1
SD score are sufficient for the strong suspicion of GHD
according to the German diagnostic guidelines (2). A definite
diagnosis is established by two stimulation tests with a
human growth hormone (hGH) peak below an arbitrary cut-
off of 5–10 ng/mL (2, 3) as decision cut-point. Measured
hGH values can vary remarkably depending on the assay
method used (4). Reasons for the variability of immunoassay
results are the preparation of assay calibrators, specificity of
antibodies, assay design (sandwich vs. competitive), matrix
differences between standards and samples, and interferences
with endogenous human growth hormone binding protein
(hGHBP) (5). Inter-laboratory tests of the German Society
of Clinical Chemistry and Laboratory Medicine with syn-
thetic test samples showed a coefficient of variation (CV)
for hGH measurements between 18% and 36% for more than
20 immunoassays that were used in 2009 (4). However, syn-
thetic control samples may not reflect all the potential inter-
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Figure 1 Number of serum samples in dependence on measured
hGH levels by the IMMULITE 2000 fully automated system.
Table 1 Technical information for the 8 assays used for the measurement of hGH.
Method Analytical Precision Specificity Reference Conversion
(Manufacturer) sensitivity, (coefficient of preparation factor,
ng/mL variation) ng=x smU
AutoDELFIA 0.012 0.6%–3.7% No 20 kDa hGH WHO 1. IS 80/505 2.6
(PerkinElmer) (3.2–13 ng/mL)
4.7%–13%
(3.3–13.3 ng/mL)
DxI 0.002 2.1%–3.2% No 20 kDa hGH WHO 2. IS 98/574 3
(Beckmann-Coulter) (2.5–14.1 ng/mL)
ELISA 0.0016 3.1%–6% WHO 2. IS 98/574 3
(Mediagnost) (2.4–14.3 ng/mL)
IMMULITE 2000 0.01 4.2%–6.6% WHO 2. IS 98/574 3
(Siemens) (2.6–17 ng/mL)
BC-IRMA 0.01 5.7%–10.1% WHO 1. IS 88/624 3
(Beckmann-Coulter) (0.6–5.2 ng/mL)
iSYS 0.05 2.7%–6.1% No 20 kD hGH WHO 2. IS 98/574 3
(IDS) (1.7–26.8 ng/mL)
Liaison Max. 0.052 2.2%–3.1% WHO 2. IS 98/574 3
(DiasSorin) (2.5–10.2 ng/mL)
RIA (in house) 0.05 2.2%–7.6% WHO 2. IS 98/574 3
Tu¨bingen (2.5–10.2 ng/mL)
DxI, UniCel DxI 800 Access; ELISA, Mediagnost ELISA E022; BC-IRMA, BC-BC-IRMA; iSYS, IDS-iSYS; RIA, In-house RIA Tu¨bingen;
Hb, haemoglobin; TG, triglycerides; hLH, human luteinizing hormone.
fering factors in an immunoassay. To evaluate the compar-
ability of hGH immunoassay measurements in serum of chil-
dren and adolescents, we tested seven commercially availa-
ble methods frequently used in clinical practice, as well as
an in-house radioimmunoassay (RIA). Then, we reduced the
variability between these assays using three different math-
ematical harmonization procedures: linear regression analy-
sis, conversion factors and quantile transformation. The aim
of our study was to assess which adjusting procedure per-
forms best in harmonizing growth hormone measurements
and in improving comparability of GHD diagnosis.
Materials and methods
Samples
A total of 168 samples from male patients and 144 samples from
female patients with suspected GHD ranging in age from 17 days
to 17 years were collected from surplus sera from stimulation tests
and from the evaluation of spontaneous hGH secretion at the pedi-
atric departments of the universities of Leipzig, Tu¨bingen, and
Berlin.
The mean age"SD of our patients was 8.00"3.44 years (ns
312). The initially documented hGH concentrations of all sera were
between 0 and 15 ng/mL (Figure 1).
Two hundred and sixty-two samples were from results of single
blood collections, 23 derived from two pooled samples of patients
having comparable hGH concentrations and similar age, 27 derived
from two pooled samples from the same child containing similar
hGH concentrations (mean differences"standard deviation: 0.27"
0.38 ng/mL). Pools were made to achieve adequate volume for our
analytical determination. The samples were stored at a minimum of
-–258C until determination of hGH. The study was reviewed and
approved by the Ethic Committee of the University of Leipzig.
HGH measurement
HGH concentrations of serum samples were investigated by a mul-
ticentre study using eight different immunoassays. Five were fully
automated (AutoDELFIA, PerkinElmer; IMMULITE 2000, Sie-
mens; iSYS, IDS; Liaison, DiaSorin; UniCel DxI 800 Access,
BeckmanCoulter) and three were performed using a manual pro-
cedure (BC-IRMA, BeckmanCoulter; ELISA, Mediagnost; ‘‘In
house’’-RIA, Tu¨bingen). All samples were processed between June
2008 and January 2010. Technical information about method-
dependent calibrator and analytical specifications is given in Table 1.
The only non-commercially available assay was a competitive hGH-
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Figure 2 Example calculation how a single GH measurement transforms when using quantile transformation.
Table 2 Descriptive analysis for all samples (ns312) measured by the different hGH assay methods.
Mean"SD, Median, Perc 25–75, Min–Max,
ng/mL ng/mL ng/mL ng/mL
AutoD 5.62"3.84 4.95 2.44–8.58 0.04–16.5
DxI 3.91"2.76 3.46 1.62–6.05 0.03–12.74
ELISA 3.91"2.75 3.55 1.71–5.88 0.01–13.83
Immulite 5.90"3.77 5.44 2.95–8.51 0.06–14.80
BC-IRMA 3.19"2.36 2.67 1.39–5.00 0.01–11.30
iSYS 5.28"3.52 4.55 2.71–7.40 0.14–15.71
Liaison 4.76"3.16 4.20 2.20–7.10 0.10–15.20
RIA 4.25"2.43 3.90 2.20–5.90 0.80–11.70
All assays 4.50"3.18 3.99 1.99–6.50 0.01–16.50
AutoD, AutoDELFIA; DxI, UniCel DxI 800 Access; ELISA, Mediagnost ELISA E022. Immulite, IMMULITE 2000. BC-IRMA, Beckman-
Coulter immunoradiometric assay; iSYS, IDS-iSYS; RIA, In-house RIA Tu¨bingen; SD, standard deviation; xmin, minimum value; xmax,
maximum value; Perc 25, 25th percentile; Perc 75, 75th percentile.
RIA developed and employed at the Children’s Hospital in Tu¨bingen
(6).
Statistical methods
The total number of measured growth hormone concentrations was
not normally distributed. Therefore, we used Spearman’s correlation
statistics which was also interpreted as a measure of comparability
between two assays.
Data analysis was performed using Microsoft Office Excel 2003.
Linear regression analysis for the comparison of results from dif-
ferent methods was performed according to Passing-Bablok (7)
using MedCalc (MedCalc Software, 9030 Mariakerke, Belgium).
As another mean to harmonize the data, we performed quantile
normalization, a method adopted from microarray normalization (8).
With this method, the percentiles of the empirical distributions of
hGH concentrations were determined for each of the eight assays
separately. Due to the lack of a gold-standard or reference scale, we
defined a common ‘‘reference’’ of all assays by ‘‘averaging’’ the
assay percentiles. More precisely, we calculated the percentiles of
the common ‘‘reference’’ by taking the median of the matching
percentiles of the eight assays. Finally, all single assay measure-
ments were mapped to the common ‘‘reference’’ using their respec-
tive intra-assay percentiles. That is, a single measurement is mapped
to the inter-assay median of the matching intra-assay percentile.
Figure 2 illustrates the procedure in more detail. Calculations were
performed using the statistical software package R (www.r-pro-
ject.org). The corresponding R-script and a running example can be
found in the Annex.
To assess the effect of the different normalization methods used,
we calculated the inter-assay coefficients of variation before and
after the normalization steps. Different ranges (-1, 1–4.99, 5–9.99,
G10) of hGH concentrations were used to assess the performance
of the normalization methods for different groups of patients.
Results
Comparison of hGH levels measured
By using the eight different methods noted above for the
measurement of hGH we obtained values ranging from 0.01
to 16.50 ng/mL (Table 2). The mean value of all measure-
ments was 4.60 ng/mL, the median was 4.10 ng/mL. HGH
results from the IMMULITE 2000 (median: 5.44 ng/mL)
were found to be considerably higher than the overall medi-
an. The lowest hGH concentrations of all assays were from
the BC-IRMA (median: 2.67 ng/mL). The medians of meas-
urements by the AutoDELFIA (median: 4.95 ng/mL), Liai-
son (4.20 ng/mL), iSYS (4.55 ng/mL), RIA (3.90 ng/mL),
ELISA (3.55 ng/mL), and DxI (3.46 ng/mL) were distributed
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Table 3 Coefficient of variation for all samples within a defined concentration range consistent with all 8 immunoassays.
CV (%) after using hGH, ng/mL
-1 1–4.99 5–9.99 G10
Raw data 68.2%"45.6% 28.2%"11.0% 24.3%"7.4% 24.0%"7.7%
(ns33) (ns105) (ns118) (ns56)
Calibrator 98/574 only 63.7%"39.7% 23.4%"13.3% 17.3%"9.6% 19.9%"10.8%
(ns33) (ns105) (ns118) (ns56)
No 20 kDa GH specific only 41.9%"36.1% 27.0%"13.0% 24.1%"10.2% 26.9%"10.0%
(ns33) (ns105) (ns118) (ns33)
Linear regression 32.3%"29.0% 15.4%"11.7% 13.2%"7.6% 12.5%"8.3%
(ns33) (ns105) (ns118) (ns56)
Conversion factor 69.1%"48.3% 17.7%"10.6% 12.6%"7.6% 15.9%"9.2%
(ns37) (ns153) (ns103) (ns19)
Quantile transformation 34.6%"44.3% 13.4%"9.5% 11.4%"7.6% 13.0%"5.7%
(ns38) (ns155) (ns106) (ns13)
Results for ‘‘Calibrator 98/574 only’’ contain values of those 5 immunoassays calibrated with IS 98/574. ‘‘No 20 kDa hGH specific only’’
contains data of the 3 immunoassays specific to the 22 kDa isoform of hGH (AutoDELFIA, UniCel DxI 800 Access, IDS-iSYS).
between the IMMULITE and BC-IRMA data. The maximum
difference between individual measurements by different
methods was 11.4 ng/mL. The mean differences of GH
concentrations measured by specific assays ranged from
0.36 ng/mL (DxI vs. ELISA) to 2.71 ng/mL (IMMULITE
vs. BC-IRMA).
Individual assay results from different methods were com-
pared by correlation analysis. Coefficients of correlations
varied between rs0.992 for the comparison between
AutoDELFIA with Liaison, and rs0.864 for the comparison
between iSYS and in-house RIA.
The median CV of all samples and methods in the poten-
tial clinically relevant cut-off range between 5 and 10 ng/mL
(ns118) was 24.3%"7.4% (mean"SD, see also Table 3).
After adjustment for the biological potency of the internatio-
nal reference preparations used in each assay, we obtained a
comparable CV of 24.3%"8.6%. After exclusion of meth-
ods not calibrated against the latest reference preparation of
the WHO (98/574), the CV was calculated to be 17.3%"
9.6% (Table 3). Considering just the three methods that spe-
cifically measure the 22 kDa isoform of hGH by use of
monoclonal antibodies, the CV was 24.1%"10.2%. For this
calculation we had to consider carefully the different refer-
ence preparations used by the manufacturers. Thus, we mul-
tiplied all results of AutoDELFIA by the factor of 1.154,
which was calculated as the ratio of the conversion factors
3 mU/L and 2.6 mU/L.
Procedures for the adjustment of data
In a next step, we aimed to adjust the different hGH con-
centrations of the individual assay methods to the results of
the IMMULITE system which was arbitrarily defined as a
reference standard (y) by linear regression analysis. The
individual Passing-Bablok regression equations were, for
AutoDELFIA ys1.034xq0.207; Dxl ys1.387xq0.356;
ELISA ys1.394xq0.267; BC-IRMA ys1.684xq0.443;
iSYS ys1.109xq0.043, Liaison ys1.272xq0.023 and
RIA ys1.571x–0.971. If these equations were applied to all
non-IMMULITE hGH measurements, we observed a dis-
tinctly decreased CV of the transformed data: 13.2%"7.6%
(Table 3).
The following step involved the calculation of conversion
factors, which are another and much more practical tool for
the linear transformation of hGH values, and therefore better
comparable results. For this purpose, we selected all samples
containing a hGH concentration in the putative range for the
decision GHD or non-GHD between 5.0 and 10 ng/mL
according to the Immulite assay (ns78). Then, we calculat-
ed the ratio between the mean value of all measurements of
all assays (as the arbitrary gold standard) and the mean value
of all measurements from each individual assay. The mean
concentration of these 78 samples measured by all assays
was 6.27 ng/mL. The mean concentration of the same sam-
ples measured, for example, by the AutoDELFIA method
was 7.73 ng/mL; accordingly, the conversion factor for the
AutoDELFIA method was 0.81. The remaining conversion
factors were calculated to be 1.13 for DxI; 1.11 for ELISA;
0.80 for IMMULITE 2000; 1.47 for BC-IRMA; 0.91 for
iSYS; 0.97 for Liaison; 1.08 for RIA. The mean CV value
after applying this transformation was 12.6%"7.6% in the
cut-off range between 5 and 10 ng/mL (Table 3).
Finally, we used quantile transformation as a novel nor-
malization procedure. All hGH data were ranked and per-
centiles were determined for the individual assays. As a
reference, the median of all assay values for a particular per-
centile was defined. The transformed value of any sample
derived from its percentile after ranking and corresponds to
the value of the reference at the same percentile. Applying
this procedure, the mean CV value was reduced to 11.4%"
7.6% in the cut-off range between 5 and 10 ng/mL (Table 3).
Consequences for the diagnostic confirmation
of GHD
The effect of different statistical procedures for the adjust-
ment of hGH measurements on the diagnosis of GHD was
assessed as shown in Table 4. If a hGH concentration of
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Table 4 Influence of different tools for data transformation on the diagnosis GHD (%) at two different cut-off points.
Cut-off GHD according to GHD after linear GHD after conversion GHD after quantile
raw data, % regression, % factor, % transformation, %
6 ng/mL 8 ng/mL 6 ng/mL 8 ng/mL 6 ng/mL 8 ng/mL 6 ng/mL 8 ng/mL
AutoD 61.9 70.8 58.0 69.6 69.2 83.3 70.5 86.2
DxI 74.7 91.7 57.8 72.8 69.9 84.9 70.2 86.5
ELISA 76.0 92.0 57.8 72.8 71.8 84.9 70.5 86.5
Immulite 57.4 70.5 57.4 70.5 68.3 82.1 70.5 85.9
BC-IRMA 85.9 97.1 59.9 70.5 68.6 80.1 70.5 86.5
iSYS 65.4 78.5 59.3 73.7 67.9 82.4 70.5 86.5
Liaison 67.9 81.7 57.1 69.2 68.9 83.3 70.5 86.5
RIA 75.3 91.7 55.1 73.4 70.8 87.8 69.9 86.5
CV, % 13.0 12.3 2.5 2.5 1.9 2.8 0.3 0.3
AutoD, AutoDELFIA; DxI, UniCel DxI 800 Access; ELISA, Mediagnost ELISA E022; Immulite, IMMULITE 2000; BC-IRMA, Beckman-
Coulter immunoradiometric assay; iSYS, IDS-iSYS; RIA, In-house RIA Tu¨bingen; CV, coefficient of variation; Lin. Regr., linear regression;
Quant. Transf., quantile transformation; GHD, growth hormone deficiency.
6 ng/mL would be defined as a cut-off (and all samples
examined would be peak samples from stimulation tests),
GHD would be diagnosed in 179 out of 312 children by the
IMMULITE 2000 system, whereas the BC-IRMA would
detect 268 cases. Accordingly, the diagnosis of 29% of the
investigated children would be dependent on the immuno-
assay used. An increased cut-off of 8 ng/mL would not
change this outcome substantially: 27% would have an
assay-dependent diagnosis. This assay dependence was
effectively reduced by adjustment of the hGH values meas-
ured using linear regression or conversion factor to below
8%, and by application of quantile normalization to below
1% for both cut-offs.
Discussion
This is, to the best of our knowledge, the most comprehen-
sive study dealing with comparability of assays measuring
hGH concentrations in children and adolescents. For eight
frequently used hGH assays we calculated a median CV of
24.3% for concentrations between 5 and 10 ng/mL hGH. As
the actual cut-off for the diagnosis of GHD in children and
adolescents is within this concentration range, the diagnostic
decision depends strongly on the accuracy and the precision
of the laboratory method that is used. Accordingly, only a
low degree of comparability was observed if these methods
were used to diagnose GHD in our sera. To overcome this
dilemma we investigated two different approaches: 1) har-
monization by assay standardization (reference and anti-
body), 2) harmonization of assay results by statistical
methods.
Regarding the assay standardization-based approach, we
found that the restriction to only the single calibrator IS
98/574 led to an improved between-assay CV from 24.3%
to 17.3%. These data are similar to findings reported by Ross
(9) who demonstrated that a unique reference preparation
decreased the between-assay CV of six hGH immunoassays
from 25% to 15% when six samples were included in the
statistical calculation. Additionally, according to Tanaka et
al. (10), the restriction to a unique recombinant hGH stan-
dard (60 samples, six assays) resulted in a decrease of the
between assay CV from 35% to 18%. This improvement led
to the recent agreement that all manufacturers of hGH immu-
noassay kits in Japan need to use the same recombinant ref-
erence preparation for calibration purposes. Furthermore,
neither transformation to international units (CV: 24.3%) nor
considering only 22 kDa specific assays (CV: 24.1%), as
proposed by Ebdrup et al. (11), Bidlingmaier and Freda (12)
and others, demonstrated a more substantial reduction of var-
iability in our measurements. Taking all these results togeth-
er, the standardization approach improves the comparability
of data significantly, but not satisfactorily. One may speculate
that a lack of cross-reactivity with the 20 kDa hGH isoform
alone, as it has been documented for three assays, is not
sufficient for complete standardization of antigen-antibody
interaction. Different levels of aggregates and cleavage of
the 22 kDa monomer may be recognized differently even by
monoclonal antibodies (13). Moreover, hGHBP may have a
modulating effect on hGH results, although we did not find
significant correlations between hGH and hGHBP concen-
trations in our samples (data not shown). Of particular con-
cern, if the incubation period in the assay is relatively short,
as for example 2 h in most of our methods, or if the affinity
constant of the antibody to the 22 kDa isoform is only slight-
ly higher than that of hGHBP, the probability for a confound-
ing interaction by this binding protein could be high (11,
14).
To improve the comparability of our hGH results indepen-
dently from the standardization of assay components, we
searched for a statistical method that is able to harmonize
hGH results: adjusting our data by linear regression led to a
decrease in the CV from 24.3% to 13.2%. Linear regression
has already been suggested in some papers for the harmo-
nization of hGH. Tanaka et al. (10) concluded that correcting
hGH values by this method could indeed enhance the equal-
ity of the diagnosis of GHD. We next assessed a conversion
factor as a second statistical tool for linearly associated data.
Its application resulted in satisfactory reduction of the CV
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Figure 3 Passing-Bablok residual plots for the comparison between individual assays and the results of the IMMULITE 2000.
from 24.3% to 12.6%. Theoretically, a harmonization serum
that enables establishment of a conversion factor for each
individual assay run could further reduce this CV to below
10%, as shown recently for six samples by a panel of six
methods (9).
However, the use of linear methods for data adjustment is
debatable. Recently, Hauffa et al. investigated the use of lin-
ear transformation methods for the adjustment of hGH con-
centrations from different assays (6). HGH concentrations
from this study were not linearly associated over the whole
range up to approximately 100 mU/L, but linearity appeared
to be given for the hGH concentration range relevant for the
diagnosis of GHD. Amed et al. (15) investigated hGH in 101
samples from children in a comparison of five assay meth-
ods. They evidenced scatter in their results that suggests non-
linearity restricted to a concentration range from the
detection limit to approximately 5 ng/mL hGH. In contrast
to both papers, we observed largely linear associations of
hGH concentrations in all our assays by the Passing-Bablok
method for the range up to the decision threshold for the
diagnosis GHD; between 0 and 8 ng/mL hGH, all assay com-
parisons demonstrated linearity in the data. This statement
was still valid for four comparisons if this range was extend-
ed to 10 ng/mL hGH (Figure 3, data not shown). Accord-
ingly, data transformation by linear statistics could be
achieved with an acceptable bias. However, the use of linear
statistics for harmonization does indeed have the general dis-
advantage that bias could become noticeable with increasing
deviation from the linear regression line.
Nevertheless, such methods seem to be a practical option
with minimal effort for daily practice. As shown for the
Netherlands, a central pool serum can be shipped and used
for the calculation of run-dependent conversion factors (9).
The ratio from its measuring value and the target concentra-
tion will be used for conversion of sample data.
A novel statistical approach used for hGH data harmon-
ization was quantile transformation, a non-parametric meth-
od adopted from normalization of microarray data. The only
precondition for this model was a sufficiently high number
of measurements in order to estimate required percentiles and
a monotony assumption regarding the assay data. That is, if
a person has a higher value with one assay compared to a
second person, it also should have a higher value with anoth-
er assay. Both requirements were fulfilled by our data since
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the relative standard errors of e.g., the diagnostically impor-
tant 80th and 90th percentile were moderate in size for our
sample size (between 2.7% and 5.6% depending on the
assay), and the Spearman correlation was relatively high
between all assays. Compared to the linear models, we dem-
onstrated a comparable reduction of the CV from 24.3% to
11.4%. Moreover, the degree of comparability in the diagnostic
decision was even better than for the linear procedures.
Despite such promising results, some restrictions have to
be considered for the interpretation of our data: first, we
developed a procedure for the harmonization of hGH con-
centrations, not a procedure for improving the accuracy in
the measurement of hGH. For accurate measurement of hGH,
fundamentally different approaches are needed. Non-immu-
nological methods, such as mass spectrometry could offer an
alternative as reference method or analytical routine platform
in the future (16). Second, our suggestions cannot fully
exclude a bias of comparability for the diagnosis of GHD.
The only way to avoid this would be to measure hGH in one
or more central laboratories using a single and well-suited
analytical method as currently performed in Israel. Samples
could be shipped to such central labs even as filter paper
blood spots (17). However, such an agreement is currently
unrealistic in larger countries. Third, the disadvantage of har-
monizing methods is that they have to be adjusted for sub-
stitutions of antibody or other kit components resulting in
changes of assay results for any individual method. In addi-
tion, we had to perform up to four freeze-thaw cycles before
hGH was measured in some samples. However, as it is
known that hGH is stable for five freeze-thaw cycles, we did
not expect any bias in our results (18).
We conclude, that recent recommendations for the stan-
dardization of hGH immunoassays still lead to assay-depend-
ent diagnostic decisions in approximately on one-third of
patients. The use of statistical harmonization methods to
adjust data, especially of quantile transformation, improves
the comparability of hGH from different methods and allows
a distinct reduction in the assay dependency of the laboratory
based diagnosis of GHD in these subjects. The question of
whether or not procedures for harmonization of hGH may
be applied in routine laboratory analytics, has to be discussed
by the responsive pediatric endocrine societies with regard
to a critical balance between methodological advantages and
disadvantages.
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Annex
R-script:
Example for application of quantile normalization
N--300 number of samples
define gold standard -----------------------
gold--exp(rnorm(N,sds0.2))
define alternative methods ---------------------
x1--gold*exp(rnorm(300,means0.3,sds0.1))
constant bias
x2--goldn2*exp(rnorm(300,means0,sds0.1))
different scale 1
x3--tanh(gold)*exp(rnorm(300,means0,sds0.05))
different scale 2
plots before normalization
par(mfrowsc(2,3))
plot(gold,x1)
title(‘‘before normalization’’)
abline(0,1)
plot(gold,x2)
title(‘‘before normalization’’)
abline(0,1)
plot(gold,x3)
title(‘‘before normalization’’)
abline(0,1)
data
x--cbind(x1,x2,x3)
quantile matrix, increase number of rows if needed
q--matrix(0,nrows1001,ncolslength(xw1,x))
qn--x
estimate quantiles
for (i in 1:length(xw1,x))
{
qw,ix--quantile(xw,ix,probssseq(0,1,0.001), types4)
adjust seq in accordance to q, use adequate type of quantile
estimation
}
qgold--quantile(gold,probssseq(0,1,0.001), types4)
normalization
for(j in 1:length(xw1,x))
{
ec--ecdf(xw,jx)
for (i in 1:length(xw,1x))
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{
qnwi,jx--qgoldwround(ec(xwi,jx),digitss3)*1000q1x
}}
x1n--qnw,1x
x2n--qnw,2x
x3n--qnw,3x
plots after normalization
plot(gold,x1n)
title(‘‘after normalization’’)
abline(0,1)
plot(gold,x2n)
title(‘‘after normalization’’)
abline(0,1)
plot(gold,x3n)
title(‘‘after normalization’’)
abline(0,1)
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